Top Markets
Coin of the day
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Pozycja w akcjach #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Cena akcji
$64.97
Ostatnia synchronizacja: 2024-05-20
Kapitalizacja rynkowa
$1.97B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Alpine Immune Sciences, Inc. (ALPN)

Kategoria

Historia ceny akcji dla Alpine Immune Sciences, Inc. (ALPN)
Najwyższa cena zamknięcia: $64.81 dnia 2024-05-01

Najniższa cena zamknięcia: $59.56 dnia 2015-06-01
Historia cen akcji firmy Alpine Immune Sciences, Inc. od 2015 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2024 256.53%
2023 178.29%
2022 -49.70%
2021 1.90%
2020 264.34%
2019 -23.56%
2018 -58.58%
2017 29.87%
2016 -73.99%
2015 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$548.36 40.94%
US
$1.06K 49.46%
NL
$122.63 -12.65%
AU
$140.81 461.00%
US
$765.25 7.19%
CH